Metabolism and Brain Cancer
暂无分享,去创建一个
[1] T. Kourelis,et al. Metformin and cancer: new applications for an old drug , 2012, Medical Oncology.
[2] Petr Ježek,et al. Waves of gene regulation suppress and then restore oxidative phosphorylation in cancer cells. , 2011, The international journal of biochemistry & cell biology.
[3] M. Grootveld,et al. The importance of mitochondria in the tumourigenic phenotype: gliomas as the paradigm (review). , 2011, International journal of molecular medicine.
[4] Zev A. Binder,et al. The Genetic Landscape of the Childhood Cancer Medulloblastoma , 2011, Science.
[5] S. Marie,et al. IDH1 mutations in a Brazilian series of Glioblastoma , 2011, Clinics.
[6] M. Skalej,et al. Gliomas in adults. , 2010, Deutsches Arzteblatt international.
[7] C. Larsen. [Genetic and molecular abnormalities of glioblastomas (GBM)]. , 2010, Bulletin du Cancer.
[8] C. Larsen. Anomalies génétiques et moléculaires des glioblastomes (GBM) , 2010 .
[9] Mathilde Jalving,et al. Metformin: taking away the candy for cancer? , 2010, European journal of cancer.
[10] Hai Yan,et al. Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism. , 2010, Journal of the National Cancer Institute.
[11] H. Duffau,et al. Oncological patterns of care and outcome for 952 patients with newly diagnosed glioblastoma in 2004. , 2010, Neuro-oncology.
[12] Rui Huang,et al. Glioma-derived mutations in IDH: from mechanism to potential therapy. , 2010, Biochemical and biophysical research communications.
[13] J. Mcculloch,et al. The Role of Mitochondria in Glioma Pathophysiology , 2010, Molecular Neurobiology.
[14] E. Gottlieb,et al. p53 regulation of metabolic pathways. , 2010, Cold Spring Harbor perspectives in biology.
[15] B. Tran,et al. Survival comparison between glioblastoma multiforme and other incurable cancers , 2010, Journal of Clinical Neuroscience.
[16] E. Gottlieb,et al. Targeting metabolic transformation for cancer therapy , 2010, Nature Reviews Cancer.
[17] W. Vandertop,et al. The prognostic IDH1R132 mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma , 2010, Acta Neuropathologica.
[18] R. Sun,et al. Reversal of the glycolytic phenotype by dichloroacetate inhibits metastatic breast cancer cell growth in vitro and in vivo , 2010, Breast Cancer Research and Treatment.
[19] R. Deberardinis,et al. Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer , 2010, Oncogene.
[20] G. Semenza,et al. Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression , 2010, Proceedings of the National Academy of Sciences.
[21] M. Kiebish,et al. Targeting energy metabolism in brain cancer through calorie restriction and the ketogenic diet. , 2009, Journal of cancer research and therapeutics.
[22] Eyal Gottlieb,et al. Metabolic transformation in cancer. , 2009, Carcinogenesis.
[23] N. Isern,et al. c-Myc activates multiple metabolic networks to generate substrates for cell-cycle entry , 2009, Oncogene.
[24] A. Jemal,et al. Cancer Statistics, 2009 , 2009, CA: a cancer journal for clinicians.
[25] K. Vousden. Functions of p53 in metabolism and invasion. , 2009, Biochemical Society transactions.
[26] S. Moncada,et al. The bioenergetic and antioxidant status of neurons is controlled by continuous degradation of a key glycolytic enzyme by APC/C–Cdh1 , 2009, Nature Cell Biology.
[27] L. Cantley,et al. Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation , 2009, Science.
[28] Keshav K. Singh,et al. p53 regulates mtDNA copy number and mitocheckpoint pathway , 2009, Journal of carcinogenesis.
[29] G. Shadel,et al. Loss of p53 causes mitochondrial DNA depletion and altered mitochondrial reactive oxygen species homeostasis. , 2009, Biochimica et biophysica acta.
[30] Kun-Liang Guan,et al. Glioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1α , 2009, Science.
[31] A. Merlo,et al. Translating biology into clinic: the case of glioblastoma. , 2009, Current opinion in cell biology.
[32] S. Marie,et al. ICAM-1 (Lys469Glu) and PECAM-1 (Leu125Val) polymorphisms in diffuse astrocytomas , 2009, Clinical and Experimental Medicine.
[33] Antonio G. Cordente,et al. C75 is converted to C75-CoA in the hypothalamus, where it inhibits carnitine palmitoyltransferase 1 and decreases food intake and body weight. , 2009, Biochemical pharmacology.
[34] Xiaojun Xu,et al. Transketolase‐like protein 1 (TKTL1) is required for rapid cell growth and full viability of human tumor cells , 2009, International journal of cancer.
[35] Russell G. Jones,et al. Tumor suppressors and cell metabolism: a recipe for cancer growth. , 2009, Genes & development.
[36] C. Thompson,et al. Metabolic enzymes as oncogenes or tumor suppressors. , 2009, The New England journal of medicine.
[37] Yau-Huei Wei,et al. Mitochondrial DNA Instability and Metabolic Shift in Human Cancers , 2009, International journal of molecular sciences.
[38] Hua Li,et al. Structural and Biochemical Studies of TIGAR (TP53-induced Glycolysis and Apoptosis Regulator)* , 2009, Journal of Biological Chemistry.
[39] A. Marchetti,et al. IDH1 mutations at residue p.R132 (IDH1R132) occur frequently in high‐grade gliomas but not in other solid tumors , 2009, Human mutation.
[40] S. Ben-Haim,et al. 18F-FDG PET and PET/CT in the Evaluation of Cancer Treatment Response* , 2008, Journal of Nuclear Medicine.
[41] Anthony Mancuso,et al. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction , 2008, Proceedings of the National Academy of Sciences.
[42] M. Couce,et al. Differences in Mitochondrial Function and Antioxidant Systems between Regions of Human Glioma , 2008, Cellular Physiology and Biochemistry.
[43] Ralph Weissleder,et al. Effective Use of PI3K and MEK Inhibitors to Treat Mutant K-Ras G12D and PIK3CA H1047R Murine Lung Cancers , 2008, Nature Medicine.
[44] M. Kiebish,et al. Targeting energy metabolism in brain cancer with calorically restricted ketogenic diets , 2008, Epilepsia.
[45] W. Kaelin. The von Hippel–Lindau tumour suppressor protein: O2 sensing and cancer , 2008, Nature Reviews Cancer.
[46] W. Plunkett,et al. Nucleoside analogs: molecular mechanisms signaling cell death , 2008, Oncogene.
[47] P. Lotufo,et al. Association of EGFR c.2073A>T polymorphism with decreased risk of diffusely infiltrating astrocytoma in a Brazilian case-control study. , 2008, The International journal of biological markers.
[48] D. Busam,et al. An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2008, Science.
[49] D. Sabatini,et al. Cancer Cell Metabolism: Warburg and Beyond , 2008, Cell.
[50] Joshua M. Korn,et al. Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.
[51] M.-H. Lee,et al. Roles of p53, Myc and HIF-1 in Regulating Glycolysis — the Seventh Hallmark of Cancer , 2008, Cellular and Molecular Life Sciences.
[52] Robert A. Harris,et al. Pyruvate Dehydrogenase Complex Activity Controls Metabolic and Malignant Phenotype in Cancer Cells* , 2008, Journal of Biological Chemistry.
[53] R. Perona,et al. Epidermal growth factor receptor and glioblastoma multiforme: molecular basis for a new approach , 2008, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.
[54] A. Regev,et al. An embryonic stem cell–like gene expression signature in poorly differentiated aggressive human tumors , 2008, Nature Genetics.
[55] Nobuyuki Tanaka,et al. p53 regulates glucose metabolism through an IKK-NF-κB pathway and inhibits cell transformation , 2008, Nature Cell Biology.
[56] Suely K. N. Marie,et al. Gene expression profile analysis of primary glioblastomas and non-neoplastic brain tissue: identification of potential target genes by oligonucleotide microarray and real-time quantitative PCR , 2008, Journal of Neuro-Oncology.
[57] M. Knopp,et al. Synergistic Antipancreatic Tumor Effect by Simultaneously Targeting Hypoxic Cancer Cells With HSP90 Inhibitor and Glycolysis Inhibitor , 2008, Clinical Cancer Research.
[58] H. Christofk,et al. Pyruvate kinase M2 is a phosphotyrosine-binding protein , 2008, Nature.
[59] Ru Wei,et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth , 2008, Nature.
[60] A. Camargo,et al. Maternal embryonic leucine zipper kinase transcript abundance correlates with malignancy grade in human astrocytomas , 2008, International journal of cancer.
[61] John O Trent,et al. Small-molecule inhibition of 6-phosphofructo-2-kinase activity suppresses glycolytic flux and tumor growth , 2008, Molecular Cancer Therapeutics.
[62] R. Deberardinis,et al. Beyond aerobic glycolysis: Transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis , 2007, Proceedings of the National Academy of Sciences.
[63] L. Chin,et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. , 2007, Genes & development.
[64] D. Hardie,et al. AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy , 2007, Nature Reviews Molecular Cell Biology.
[65] P. Pedersen,et al. Warburg, me and Hexokinase 2: Multiple discoveries of key molecular events underlying one of cancers’ most common phenotypes, the “Warburg Effect”, i.e., elevated glycolysis in the presence of oxygen , 2007, Journal of bioenergetics and biomembranes.
[66] B. Scheithauer,et al. The 2007 WHO Classification of Tumours of the Central Nervous System , 2007, Acta Neuropathologica.
[67] Nicola Zamboni,et al. Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells , 2007, The Journal of cell biology.
[68] S. K. Nagahashi Marie,et al. Expression of HOXC9 and E2F2 are up-regulated in CD133(+) cells isolated from human astrocytomas and associate with transformation of human astrocytes. , 2007, Biochimica et biophysica acta.
[69] Wenzhe Ma,et al. A pivotal role for p53: balancing aerobic respiration and glycolysis , 2007, Journal of bioenergetics and biomembranes.
[70] Yusuke Nakamura,et al. Mutation of RRM2B, encoding p53-controlled ribonucleotide reductase (p53R2), causes severe mitochondrial DNA depletion , 2007, Nature Genetics.
[71] P. Kleihues,et al. Genetic pathways to primary and secondary glioblastoma. , 2007, The American journal of pathology.
[72] C. Scrideli,et al. Prognostic significance of co-overexpression of the EGFR/IGFBP-2/HIF-2A genes in astrocytomas , 2007, Journal of Neuro-Oncology.
[73] Monica L. Mo,et al. Global reconstruction of the human metabolic network based on genomic and bibliomic data , 2007, Proceedings of the National Academy of Sciences.
[74] Gary L Gallia,et al. PIK3CA Gene Mutations in Pediatric and Adult Glioblastoma Multiforme , 2006, Molecular Cancer Research.
[75] Chi V Dang,et al. Cancer's molecular sweet tooth and the Warburg effect. , 2006, Cancer research.
[76] Saroj P. Mathupala,et al. Hexokinase II: Cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria , 2006, Oncogene.
[77] D. Green,et al. p53 and Metabolism: Inside the TIGAR , 2006, Cell.
[78] Oksana Gavrilova,et al. p53 Regulates Mitochondrial Respiration , 2006, Science.
[79] P. Leder,et al. Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. , 2006, Cancer cell.
[80] E. T. Gawlinski,et al. Acid-mediated tumor invasion: a multidisciplinary study. , 2006, Cancer research.
[81] Thomas D. Wu,et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. , 2006, Cancer cell.
[82] G. Semenza,et al. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. , 2006, Cell metabolism.
[83] Y. Yoon,et al. Increased production of reactive oxygen species in hyperglycemic conditions requires dynamic change of mitochondrial morphology. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[84] Eyal Gottlieb,et al. Mitochondrial tumour suppressors: a genetic and biochemical update , 2005, Nature Reviews Cancer.
[85] Daniel E Bauer,et al. ATP citrate lyase inhibition can suppress tumor cell growth. , 2005, Cancer cell.
[86] C. Boschek,et al. Pyruvate kinase type M2 and its role in tumor growth and spreading. , 2005, Seminars in cancer biology.
[87] S. K. Nagahashi Marie,et al. Detection of somatic TP53 splice site mutations in diffuse astrocytomas. , 2005, Cancer letters.
[88] R. Deberardinis,et al. The glucose dependence of Akt-transformed cells can be reversed by pharmacologic activation of fatty acid β-oxidation , 2005, Oncogene.
[89] Dario R Alessi,et al. Metformin and reduced risk of cancer in diabetic patients , 2005, BMJ : British Medical Journal.
[90] Martin J. van den Bent,et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.
[91] R. Mirimanoff,et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.
[92] Peng Huang,et al. Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. , 2005, Cancer research.
[93] David Beach,et al. Glycolytic enzymes can modulate cellular life span. , 2005, Cancer research.
[94] Martin G Pomper,et al. Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP. , 2004, Biochemical and biophysical research communications.
[95] R. Gillies,et al. Why do cancers have high aerobic glycolysis? , 2004, Nature Reviews Cancer.
[96] R. Sakakibara,et al. Identification and characterization of the hypoxia-responsive element of the human placental 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase gene. , 2004, Journal of biochemistry.
[97] A. Alavi,et al. Akt Stimulates Aerobic Glycolysis in Cancer Cells , 2004, Cancer Research.
[98] M. Armoni,et al. The Tumor Suppressor p53 Down-Regulates Glucose Transporters GLUT1 and GLUT4 Gene Expression , 2004, Cancer Research.
[99] S. Gerson. MGMT: its role in cancer aetiology and cancer therapeutics , 2004, Nature Reviews Cancer.
[100] N. Savaraj,et al. 2-Deoxy-d-glucose Increases the Efficacy of Adriamycin and Paclitaxel in Human Osteosarcoma and Non-Small Cell Lung Cancers In Vivo , 2004, Cancer Research.
[101] S. Di Cosimo,et al. Addition of either lonidamine or granulocyte colony-stimulating factor does not improve survival in early breast cancer patients treated with high-dose epirubicin and cyclophosphamide. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[102] B. Dutrillaux,et al. Phase II Study of Lonidamine and Diazepam in the Treatment of Recurrent Glioblastoma Multiforme , 2003, Journal of Neuro-Oncology.
[103] Keshav K. Singh,et al. Mitochondrial impairment in p53-deficient human cancer cells. , 2003, Mutagenesis.
[104] Paolo Carlini,et al. Lonidamine: efficacy and safety in clinical trials for the treatment of solid tumors. , 2003, Drugs of today.
[105] M. Berger,et al. Epidemiology of primary brain tumors: current concepts and review of the literature. , 2002, Neuro-oncology.
[106] N. Sang,et al. Hypoxia-inducible Factor-1-mediated Expression of the 6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 (PFKFB3) Gene , 2002, The Journal of Biological Chemistry.
[107] P. Vaupel,et al. Pyruvate kinase type M2: a crossroad in the tumor metabolome , 2002, British Journal of Nutrition.
[108] Saroj P. Mathupala,et al. Glucose Catabolism in Cancer Cells , 2001, The Journal of Biological Chemistry.
[109] T. Yoshihara,et al. Localization of Cytosolic NADP-dependent Isocitrate Dehydrogenase in the Peroxisomes of Rat Liver Cells , 2001, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[110] M. Gorospe,et al. Pharmacological inhibition of fatty acid synthase activity produces both cytostatic and cytotoxic effects modulated by p53. , 2001, Cancer research.
[111] M. Guida,et al. Paclitaxel, cisplatin and lonidamine in advanced ovarian cancer. A phase II study. , 2001, European journal of cancer.
[112] M. Ducreux,et al. A phase II study: docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma. , 2000, European journal of cancer.
[113] B. Geisbrecht,et al. The Human PICD Gene Encodes a Cytoplasmic and Peroxisomal NADP+-dependent Isocitrate Dehydrogenase* , 1999, The Journal of Biological Chemistry.
[114] Linet,et al. RESPONSE: Re: Brain and Other Central Nervous System Cancers: Recent Trends in Incidence and Mortality. , 1999, Journal of the National Cancer Institute.
[115] Richard A. Roth,et al. Regulation of GLUT1 Gene Transcription by the Serine/Threonine Kinase Akt1* , 1999, The Journal of Biological Chemistry.
[116] G. Semenza,et al. Oncogenic alterations of metabolism. , 1999, Trends in biochemical sciences.
[117] C. Prives,et al. The p53 pathway , 1999, The Journal of pathology.
[118] P. Ratcliffe,et al. Hypoxia and the regulation of gene expression. , 1998, Molecular medicine today.
[119] Saroj P. Mathupala,et al. Glucose Catabolism in Cancer Cells , 1997, The Journal of Biological Chemistry.
[120] D. Vertommen,et al. Phosphorylation and Activation of Heart 6-Phosphofructo-2-kinase by Protein Kinase B and Other Protein Kinases of the Insulin Signaling Cascades* , 1997, The Journal of Biological Chemistry.
[121] G. Semenza,et al. Hypoxia Response Elements in the Aldolase A, Enolase 1, and Lactate Dehydrogenase A Gene Promoters Contain Essential Binding Sites for Hypoxia-inducible Factor 1* , 1996, The Journal of Biological Chemistry.
[122] G. Semenza,et al. Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. , 1994, The Journal of biological chemistry.
[123] Z. Ram,et al. Selective activity of phenylacetate against malignant gliomas: resemblance to fetal brain damage in phenylketonuria. , 1994, Cancer research.
[124] Douglas C. Miller,et al. A Correlative Study of p53 Protein Alteration and p53 Gene Mutation in Glioblastoma Multiforme , 1993, Brain pathology.
[125] R. Haselbeck,et al. Function and expression of yeast mitochondrial NAD- and NADP-specific isocitrate dehydrogenases. , 1993, The Journal of biological chemistry.
[126] D. Lane,et al. Regulation of the specific DNA binding function of p53 , 1992, Cell.
[127] Bert Vogelstein,et al. p53 function and dysfunction , 1992, Cell.
[128] L. Strong,et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. , 1990, Science.
[129] B. Vogelstein,et al. A genetic model for colorectal tumorigenesis , 1990, Cell.
[130] B. S. Winkler,et al. Multiple NADPH-producing pathways control glutathione (GSH) content in retina. , 1986, Experimental eye research.
[131] H. Rosenfeld,et al. Enhancement of antitumor activity of glutamine antagonists 6-diazo-5-oxo-L-norleucine and acivicin in cell culture by glutaminase-asparaginase. , 1981, Cancer research.
[132] E. Alexander,et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. , 1978, Journal of neurosurgery.
[133] J. Fraumeni,et al. Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? , 1969, Annals of internal medicine.
[134] O. Warburg. [Origin of cancer cells]. , 1956, Oncologia.
[135] J. A. Robinson. Clinics , 1883, The Dental register.
[136] S. Marie,et al. Mitochondrial DNA depletion and its correlation with TFAM, TFB1M, TFB2M and POLG in human diffusely infiltrating astrocytomas. , 2011, Mitochondrion.
[137] G. Reifenberger,et al. MGMT promoter methylation in malignant gliomas: ready for personalized medicine? , 2010, Nature Reviews Neurology.
[138] J. Griffiths,et al. The altered metabolism of tumors: HIF-1 and its role in the Warburg effect. , 2010, Advances in enzyme regulation.
[139] Tsung-Cheng Chang,et al. c-Myc suppression of miR-23 enhances mitochondrial glutaminase and glutamine metabolism , 2009, Nature.
[140] F. Ducray,et al. IDH1 and IDH2 mutations in gliomas. , 2009, The New England journal of medicine.
[141] R. Deberardinis,et al. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. , 2008, Cell metabolism.
[142] D. Louis. WHO classification of tumours of the central nervous system , 2007 .
[143] L. D.,et al. Brain tumors , 2005, Psychiatric Quarterly.
[144] P. Schubert,et al. Mutations in the transketolase-like gene TKTL1: clinical implications for neurodegenerative diseases, diabetes and cancer. , 2005, Clinical laboratory.
[145] M. Colombini. VDAC: The channel at the interface between mitochondria and the cytosol , 2004, Molecular and Cellular Biochemistry.
[146] B. Amir-Ahmady,et al. Dietary regulation of expression of glucose-6-phosphate dehydrogenase. , 2001, Annual review of nutrition.
[147] Y. Nakamura,et al. Identification of seven genes regulated by wild-type p53 in a colon cancer cell line carrying a well-controlled wild-type p53 expression system. , 1999, Oncology research.
[148] P. Huppert,et al. Expression of hypoxia-inducible genes in tumor cells , 1998, Journal of Cancer Research and Clinical Oncology.
[149] M. Hollstein,et al. Clinical implications of the p53 gene. , 1996, Annual review of medicine.
[150] E. Eigenbrodt,et al. Double role for pyruvate kinase type M2 in the expansion of phosphometabolite pools found in tumor cells. , 1992, Critical reviews in oncogenesis.
[151] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.